Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 24)
- Beigene Ltd BGNE)
- Forte Biosciences Inc FBRX
- Pacific Biosciences of California Inc PACB
Down In The Dumps
(Biotech Stocks Hitting 52-week Lows Sept. 24)
- ADiTx Therapeutics Inc ADTX
- AEterna Zentaris Inc. AEZS
- Akebia Therapeutics Inc AKBA
- Alector Inc ALEC
- AnPac Bio-Medical Science Co Ltd – ADR ANPC
- Amarin Corporation plc AMRN
- Athira Pharma Inc ATHA
- BELLUS Health Inc BLU
- Corbus Pharmaceuticals Holdings Inc CRBP
- Cyclacel Pharmaceuticals Inc CYCC
- DBV Technologies ADR Representing 0.5 Ord Shs DBVT
- Evofem Biosciences Inc EVFM
- Fusion Pharmaceuticals Inc FUSN
- Genetron Holdings Ltd – ADR GTH
- Genfit SA GNFT
- Gritstone Oncology Inc GRTS
- Happiness Biotech Group Ltd HAPP
- Histogen Inc HSTO
- Hoth Therapeutics Inc HOTH
- Intercept Pharmaceuticals Inc ICPT
- Jaguar Health Inc JAGX
- Lexicon Pharmaceuticals, Inc. LXRX
- Natus Medical Inc NTUS
- Neos Therapeutics Inc NEOS
- Neurobo Pharmaceuticals Inc NRBO
- NextCure Inc NXTC
- Odonate Therapeutics Inc ODT
- Oncternal Therapeutics Inc ONCT
- PainReform Ltd PRFX
- Pandion Therapeutics Inc PAND
- Pliant Therapeutics Inc PLRX
- Psychemedics Corp. PMD
- RA Medical Systems Inc RMED
- Renalytix AI PLC RNLX
- Rockwell Medical Inc RMTI
- Satsuma Pharmaceuticals Inc STSA
- SCYNEXIS Inc SCYX
- Solid Biosciences Inc SLDB
- Sonnet BioTherapeutics Holdings, Inc. SONN
- Teligent Inc (NEW JERSEY) TLGT
- Theravance Biopharma Inc TBPH
- Tricida Inc TCDA
- Vaccinex Inc VCNX
- Viveve Medical Inc VIVE
- Taro Pharmaceutical Industries Ltd. TARO
Stocks In Focus
Novavax Commences Phase 3 Study of Coronavirus Vaccine Candidate
Novavax, Inc. NVAX said it has initiated its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, its COVID-19 vaccine candidate.
The trial is being conducted in the U.K. in partnership with the UK Government's Vaccines Taskforce, and is expected to enroll and immunize up to 10,000 individuals, ages 18-84 years, with and without relevant comorbidities, over the next four to six weeks, Novavax said.
Separately, Endo International PLC ENDP announced a non-exclusive agreement with Novavax to provide fill-finish manufacturing services at its plant in Rochester, Michigan for NVX-CoV2373.
In pre-market trading Friday, Novavax shares were up 7.48% to $110.10, and Endo was gaining 9.27% to $3.30.
Altimmune Rallies On Institutional Buying
Altimmune Inc ALT shares moved after a filing by the company revealed D.E. Shaw and D.E. Shaw & Co. each beneficially own 1,634,730 shares, or 5% stake in the company.
The stock rallied 8.89% to $13.10 in after-hours trading.
Clover Biopharma Announces Positive Preliminary Phase 1 Results From Coronavirus Vaccine Program
Clover Biopharma, which is developing a protein-based COVID-19 S-Trimer vaccine candidate in combination with adjuvants from GlaxoSmithKline plc GSK or Dynavax Technologies Corporation DVAX said the investigational vaccine induced a strong immune response and protection against SARS-CoV-2 in animal models.
Clover also announced preliminary results from a Phase 1 study showing that the vaccine is likely to be safe and well-tolerated, with high levels of neutralizing antibodies.
Based on these preliminary results, an additional 200 participants will be enrolled in a Phase 1 dose-expansion study at the selected S-Trimer dose-level and adjuvanted with either GSK's pandemic adjuvant or Dynavax's advanced adjuvant CpG 1018 plus alum, the company said.
Clover also said it plans to initiate a Phase 2/3 efficacy study before the end of 2020.
Genfit Announces First Patient Visit In Pivotal Phase 3 Study of Elafibranor In Primary Biliary Cholangitis
Genfit announced the first patient first visit for ELATIVE, its global, pivotal, Phase 3 study evaluating the efficacy and safety of elafibranor in primary biliary cholangitis, or PBC.
"This is a significant milestone and it means that we are now a step closer to hopefully bringing patients and caregivers a promising option to treat this debilitating disease and its symptoms. We see an important potential for elafibranor in PBC and will provide further information at the upcoming Corporate Update on September 30" said Pascal Prigent, CEO at GENFIT.
In after-hours trading, the stock jumped 13.08% to $4.15.
Radius Health, Partner Say Enrollment Into Phase 3 Study of Breast Cancer Drug Completed
Radius Health Inc RDUS and partner Menarini Group said the target enrollment milestone has been reached in the Phase 3 EMERALD clinical trial of elacestrant that is being studied in postmenopausal women and men with ER+/HER2- advanced or metastatic breast cancer.
The companies expect to conduct primary analysis of data from the study in the second half of 2021. An independent data monitoring committee that reviewed results of futility analysis conducted after the completion of 70% of targeted enrollment recommended that the study proceed without modification, the companies said.
Marinus Cleared to Initiate Registrational Phase 3 Study of Ganaxolone In Refractory Status Epilepticus
Marinus Pharmaceuticals Inc MRNS said it has satisfied the FDA's protocol-specific questions for the registrational Phase 3 trial of intravenous ganaxolone in refractory status epilepticus, allowing enrollment to begin in this clinical trial. The company expects the first patient to be enrolled in October and release topline data in the first half of 2022.
Marinus recently reported positive Phase 3 results for ganaxolone in CDKL5 deficiency disorder
In pre-market trading, the stock was adding 5.61% to $11.30.
On The Radar
Prelude Therapeutics, a clinical-stage precision oncology company, priced its initial public offering, or IPO, of 8.325 million shares at $19 per share, the upper end of the estimated price range of $17-$19. Gross proceeds from the offering are expected at $158.2 million. The shares will begin trading on the Nasdaq under the ticker symbol PRLD.
Greenwich LifeSciences Inc., a clinical-stage biopharma focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, priced its IPO of 1.261 million shares at $5.75 apiece, for raising gross proceeds of $7.25 million. The shares will begin trading on the Nasdaq under the symbol GLSI.
MV Pharmaceuticals, Inc., a precision oncology company, priced its IPO of 11.765 million shares at $18 per share. The shares are expected to begin trading on the Nasdaq under the ticker symbol PMVP.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.